How often are nonenhancing supratentorial gliomas malignant? A population study
Citation Manager Formats
Make Comment
See Comments

Abstract
The presence of contrast enhancement in a brain tumor is often regarded as a sign of malignancy. The authors identified 314 patients with malignant and low-grade supratentorial glial neoplasms in an unselected population, 58 of which lacked contrast enhancement on preoperative neuroimaging. Nonenhancing gliomas were malignant in approximately one third of cases, especially in older patients. Histologic confirmation of the diagnosis is therefore important in all patients suspected of harboring a primary glial neoplasm.
Diagnostic CT or MRI plays an important role in the initial evaluation of patients with brain tumors and the presence of contrast enhancement is often regarded as a sign of malignancy. However, this approach is limited because 14 to 45% of nonenhancing supratentorial gliomas are malignant1-7⇓⇓⇓⇓⇓⇓ and some enhancing gliomas (i.e., pilocytic astrocytoma) are benign. The risk of malignancy may increase with advancing age.6 These institutional studies contain highly selected patients and, therefore, may not reflect the true incidence in the general population or at centers that practice population-based medicine. The purpose of our study was to determine the frequency of nonenhancing malignant gliomas in an unselected population, assess the risk of malignancy in nonenhancing gliomas, and attempt to determine patient/tumor characteristics that might predict an increased risk of malignancy.
Methods.
We reviewed the records of all southern Alberta residents who were diagnosed with a glial neoplasm between January 1, 1994, and May 31, 1999, as recorded in the Alberta Cancer Registry, local hospital records, and the region’s brain tumor databases at the Tom Baker Cancer Center and Alberta Children’s Hospital. The inclusion criteria required a histologically proven supratentorial glioma in an adult or pediatric patient who had undergone preoperative contrast-enhanced CT or MRI. Classification of tumor anaplasia included low-grade glioma or subtypes (grades 1 and 2), anaplastic glioma or subtypes (grade 3), and glioblastoma multiforme (GBM, grade 4). Patients were then divided into four groups based on tumor grade (malignant vs low-grade) and contrast enhancement (present vs absent). As two groups were considered somewhat unusual, re-review of all available MRI studies for patients with nonenhancing malignant (15 of 21 cases) and contrast-enhancing low-grade gliomas (28 of 34) showed no discordance with the imaging reports.
Statistical analyses were carried out according to the Statistical Analysis System (SAS Institute Inc., SAS/STAT User’s Guide, Version 6, Fourth Edition, Cary, NC) and data expressed as mean ± SEM. Logistic regression related the risk of anaplasia in nonenhancing lesions to patient age. The operating characteristics (sensitivity, specificity, positive predictive value [PPV], negative predictive value [NPV]) of the imaging studies were calculated. As this was a population-based study, the PPV and NPV could be calculated directly.
Results.
There were 314 patients (203 men and 111 women) identified with a supratentorial glioma, including 243 malignant and 71 low-grade gliomas. Age ranged from 4 months to 87 years. Mean age was 50 years. There were 267 patients evaluated with preoperative MRI and 47 patients who only had a preoperative CT scan.
Most malignant gliomas (222/243, 91%) demonstrated contrast enhancement, and only 21 (9%) malignant gliomas lacked enhancement. The mean patient age for the enhancing malignant gliomas was 56.5 ± 1.0 years (range, 10–86), compared to 43.6 ± 3.7 years (range, 17–81; p = 0.003, t-test) for nonenhancing malignant gliomas. The majority of contrast-enhancing malignant gliomas were GBM (165 patients, 74.3%), with smaller numbers of anaplastic astrocytomas (38, 17.1%), mixed gliomas (10, 4.5%), and oligodendrogliomas (9, 4.0%). In contrast, almost all of the nonenhancing malignant gliomas (figure 1) were anaplastic astrocytomas (18, 85.7%) with only a few anaplastic mixed gliomas (2, 9.5%) or oligodendrogliomas (1, 4.8%). In this study, the probability that a contrast-enhancing glioma was malignant was high (PPV = 86.7%), although almost 37% of the nonenhancing gliomas were also malignant (NPV = 63.8%).
Figure 1. Left frontal lobe malignant astrocytoma in a 17-year-old woman. (A) Axial T2-weighted (3000/100) MRI shows an infiltrative hyperintense mass involving the parasagittal left frontal lobe. Coronal T1-weighted (600/8) (B) pre- and (C) postgadolinium images show no tumor enhancement.
In contrast to malignant gliomas, low-grade gliomas enhanced (34/71, 46.5%) about as commonly as they lacked enhancement (37/71, 53.5%; table). Patients with enhancing low-grade gliomas were younger (mean age, 27.4 ± 3.2 years) than those with nonenhancing low-grade tumors (mean age, 35.9 ± 1.7 years; p = 0.023, t-test). The group of enhancing low-grade gliomas was diverse and included many different subtypes (see the table), whereas the nonenhancing low-grade gliomas consisted almost exclusively of well-differentiated astrocytomas, oligodendrogliomas, and mixed gliomas.
Table 1 Low-grade gliomas (n = 71)
We found a trend for an increased probability of malignancy with age (figure 2). In fact, the mean patient age for those with malignant nonenhancing gliomas was 7.7 years older than those with low-grade gliomas that lacked enhancement (p = 0.07, t-test).
Figure 2. This graph shows the probability that a supratentorial nonenhancing lesion will be histologically malignant (i.e., anaplastic glioma or glioblastoma multiforme) as a function of age. The solid line represents the maximum likelihood probability according to a logistic regression model. Dashed lines represent 95% confidence bounds for the probability shown by the solid line. The dots are the individual patients with low-grade (probability of malignancy = 0.0) or malignant (probability of malignancy = 1.0) gliomas.
Discussion.
We found that contrast enhancement is not always helpful, as 9% of malignant gliomas lacked enhancement and almost 48% of low-grade gliomas enhanced. A “watch and wait” approach, without a histologic diagnosis, may therefore be inappropriate in a patient with a surgically accessible nonenhancing glioma as it could delay effective treatment in patients with malignant gliomas, particularly in older patients. We found a positive trend between the risk of anaplasia in nonenhancing gliomas and advancing age, similar to others.6 This concept is useful clinically but, in isolation, does not predict malignancy as considerable overlap in age exists between patients with malignant and nonmalignant gliomas. Other imaging modalities, such as MR spectroscopy, have promise in assessing tumors preoperatively but remain unproven in differentiating tumor subtype/grade to the level of confidence required to replace a tissue diagnosis.
Our study is population-based and the results should not be influenced by the selection biases in institutional series. We found that 9% of nonenhancing gliomas were malignant whereas others have reported higher rates (14–45%).2,4-7⇓⇓⇓⇓ It is possible that referral bias and the older age group6 may have contributed to the increased incidence in these series as any single patient would be more likely to have a malignant tumor.
We found that the group of low-grade glial neoplasms included histologic subtypes that typically enhance, such as gangliogliomas, pilocytic astrocytomas, pleomorphic xanthoastrocytomas, and subependymal giant cell astrocytomas. This group can sometimes be differentiated from malignant neoplasms based on location, young patient age, clinical presentation, or association with a neurocutaneous syndrome. We were surprised, however, to find 16 “ordinary” enhancing low-grade astrocytomas and oligodendrogliomas, although such tumors can approach 40 to 50% in some series.8-10⇓⇓ Variability in enhancement patterns likely also exists between pediatric and adult low-grade gliomas, which were combined in our study.
Our study has several limitations. Its retrospective nature is limited to existing documentation and available imaging studies that were incomplete in several cases. Although not all of our patients underwent MRI, all malignant nonenhancing gliomas did have preoperative MRI scans and our basic conclusion is therefore left intact. A few patients with contrast-enhancing low-grade and nonenhancing malignant glioma (five cases each) had only stereotactic biopsies, which are associated with sampling error and may have resulted in improper tumor grading. This issue may be more problematic in older patients who already have an increased risk of malignancy. Nonbiopsied patients with nonenhancing presumed low-grade gliomas were excluded from our study. This watchful waiting group is, by definition, more likely to be stable and would lower the incidence of nonenhancing malignant gliomas in our study if they truly represent low-grade gliomas. Finally, our description of enhancement as being either present or absent is likely overly simplistic but, unfortunately, is limited by our study’s retrospective nature. These last two points could be assessed in a prospective study in which all masses identified on imaging have objective grading of tumor enhancement prior to eventual biopsy.
Acknowledgments
Supported in part by the Alberta Cancer Board.
Acknowledgment
The authors thank the patients and their families for participating in this study; Pina Giuliano, Colette McIvor, and Marilyn Mora for technical and supportive assistance; and Eve Lee for secretarial assistance.
Footnotes
-
Presented in abstract form at the 2000 American Society of Neuroradiology meeting.
- Received January 18, 2002.
- Accepted June 5, 2002.
References
- ↵
Chamberlain MC, Murovic JA, Levin VA. Absence of contrast enhancement on CT brain scans of patients with supratentorial malignant gliomas. Neurology . 1988; 38: 1371–1374.
- ↵
- ↵
- ↵
- ↵
Perry JR, Tien RD, McLendon RE, Rasheed K, Brown MT. Argument for stereotactic biopsy of suspected low-grade glioma: results from 53 nonenhancing lesions. Neurology . 1996; 46: A158.Abstract.
- ↵
- ↵
- ↵
Lee Y-Y, Van Tassel P. Intracranial oligodendrogliomas: imaging findings in 35 untreated cases. Am J Neuroradiol . 1989; 10: 119–127.
- ↵
- ↵
Disputes & Debates: Rapid online correspondence
- correction of a statistic
- raphael petit, intern of neurology, raphael.petit7@wanadoo.fr
Submitted December 20, 2002
REQUIREMENTS
If you are uploading a letter concerning an article:
You must have updated your disclosures within six months: http://submit.neurology.org
Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.
If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.
Submission specifications:
- Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
- Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
- Submit only on articles published within 6 months of issue date.
- Do not be redundant. Read any comments already posted on the article prior to submission.
- Submitted comments are subject to editing and editor review prior to posting.
You May Also be Interested in
Related Articles
- No related articles found.